Received Jun 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 72NF3 | — |
Unstable Boostrix after temperature excursion administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incorrect storage of drug in a 26-year-old female patient who received DTPa (Reduced antigen) (Boostrix) suspension for injection in pre-filled syringe (batch number 72NF3 with expiry date 23-JUN-2028) for prophylaxis. On 01-APR-2026, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: Unstable Boostrix after temperature excursion administration). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-JUN-2026 The pharmacist had requested information regarding the administration of six vaccines. These included five Boostrix vaccines and one Engerix B vaccine. All six vaccines had undergone a temperature excursion. The maximum recorded temperature had reached 15.3-degree Celsius. The duration of the excursion had been 706 hours. As a result, the vaccines had been considered no longer stable. This case is linked with case US2026074273, reported by the same reporter.; Sender's Comments: US-GSK-US2026074273:same reporter